Collagenase <i>clostridium histolyticum</i> in patients with Dupuytren’s contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes

Warwick, David; Arner, Marianne; Pajardi, G.; Reichert, Bert; Szabó, Zsolt; Masméjean, E.; Forés, Juan Sanchı́s; Chapman, Douglass; Gerber, Robert A.; Huard, Francois; Seghouani, A.; Szczypa, Piotr

doi:10.1177/1753193413519926

Cited by 61 publications

(39 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The monitoring of progression corresponding to the 3-year CORDLESS study has been included in the series, 9 taking into account that the patients associated with the CORD I, CORD II, POINT I and POINT II studies have been excluded for the calculation of demographic data. 6,14,15 The POINT X study was also excluded 16 because it was conducted in a subgroup of patients associated with the European POINT II study. The median follow-up of patients was 265 days (range 14-1,095; standard deviation [SD]: 233 days).…”

Section: Results Of the Clinical Studiesmentioning

confidence: 99%

Efficacy of Collagenase Clostridium Histolyticum for Dupuytren Disease: A Systematic Review

Sanjuán-Cerveró¹,

Vázquez-Ferreiro

Herrero

et al. 2017

Rev Iberoam Cir Mano

View full text Add to dashboard Cite

Introduction Collagenase Clostridium Histolyticum (CCH) has become a therapeutic alternative for Dupuytren disease. However, its efficacy in the medium to long term is unknown. The objective of our study is to carry out a systematic review of the studies conducted on the subject. Material and Methods Systematic bibliographic search. Analysis depending on the time of progression, looking into 2 groups with the follow-up cut-off point of 1 year. Analysis of the number of patients who reached the primary endpoint, of the mean correction in degrees, and of the proportional correction of each joint.

show abstract

Section: Results Of the Clinical Studiesmentioning

confidence: 99%

Efficacy of Collagenase Clostridium Histolyticum for Dupuytren Disease: A Systematic Review

Sanjuán-Cerveró¹,

Vázquez-Ferreiro

Herrero

et al. 2017

Rev Iberoam Cir Mano

View full text Add to dashboard Cite

show abstract

“…By an open phase III study, conducted in 8 European countries, to test the efficacy and safety of CCH injection in patients diagnosed with Dupuytren's disease [23]. Patients were older than 18 years and were unable to place the palm and finger affection while on a surface.…”

Section: Resultsmentioning

confidence: 99%

Effectiveness Collagenase Injection in the Treatment of Patients with Dupuytren Systematic Review

Jesus¹,

Antonio²

2016

J Trauma Treat

View full text Add to dashboard Cite

Objetive: The purpose of this systematic review was to examine the scientific evidence found to determinate the effectiveness of collagenase injection in the treatment of Dupuytren´s contracture. Materials and methods:It was done through a literature search in 3 databases: PubMed, Scopus and PEDro. It was located 102 studies but only 8 clinical trial were selected because they fulfilled the criteria of inclusion and exclusion. Every clinical trial was assessed with PEDro scale. Results:In the 8 studies had a significant improvement of contracture in the patients who had an injection collagenase. The improvement is similar to proximal interphalangeal joint to Metacarpophalangeal joints. Conclusions:Despite the lack of studies about the effectiveness of this new treatment method, based on the chosen for our study we can say that the technique of collagenase can be effective in reducing the contracture caused by Dupuytren's disease.

show abstract

“…Warwick et. al haben in der multizentrischen Point X Studie 254 Patienten aus 7 verschiedenen europäischen Ländern über 6 Monate beobachtet, wobei der durchschnittliche Therapieerfolg mit einer Kontrakturreduktion von 41° angegeben wird [14]. Bei uns beträgt die durchschnittliche Kontrakturreduktion nach 6 Monaten 49°.…”

Section: Patienten Und Methodenunclassified

Therapie des Morbus Dupuytren mit Injektion von Kollagenase in Deutschland – Ergebnisse und Komplikationen an 110 Gelenken

Pototschnig¹,

Volkmer²,

Giunta³

2017

Handchir Mikrochir plast Chir

View full text Add to dashboard Cite

Since 2011, a new minimally-invasive treatment for Dupuytren's disease has been available in the form of injectable collagenase (Xiapex®, Pfizer). Our aim is to report about the results and adverse effects of injectable collagenase for the treatment of Dupuytren's disease in Germany. We treated 78 patients (61 male, 17 female) with 87 injections in 87 digits (little finger n = 40, ring finger n = 37, middle finger n = 8 and index n = 2). We documented the range of motion before treatment, after 6 weeks and after 6 months. We were able to include 39 patients (32 male, 7 female) in the 6-month follow-up. The initial correction in MCP joints (n = 26) was from an average 51° to 0° (p< 0.05). After 6 months there was an average reduction of contracture in MCP joints (n = 16) from 52° to 0° (p < 0.05). The initial correction in PIP joints (n = 28) was from an average of 63° to 15° (p < 0.05). After 6 months, PIP joints (n = 12) exhibited an average correction from 70° auf 40° (p < 0.05). In combined contractures of MCP und PIP joints (n = 33), there was a mean reduction from 96° to 13° (p < 0.05). In the 6-month follow-up, the correction of combined contractures (n = 16) was from 91° to 61° (p < 0.05). Common adverse effects were local oedema (n = 36), followed by haematoma (n = 25), temporary livid discolouration (n = 17) and skin tears (n=16). There were no severe complications such as tendon ruptures, vessel or nerve injuries. The most severe complications comprised 4 little skin defects that healed with conservative wound care. Our results are comparable with previous international studies. Very good success has been achieved with single injection treatment for high-grade preoperative contractures in MCP joints, while treatment success for combined contractures of MCP and PIP joints has been satisfactory. There have been no severe complications. Common adverse effects have been similar to previous studies. In our opinion, collagenase injection is a safe and efficient treatment for Dupuytren's disease. Further studies are needed to compare long-term efficacy with percutaneous needle aponeurotomy und partial fasciectomy.

show abstract

Collagenase clostridium histolyticum in patients with Dupuytren’s contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes

Cited by 61 publications

References 13 publications

Efficacy of Collagenase Clostridium Histolyticum for Dupuytren Disease: A Systematic Review

Efficacy of Collagenase Clostridium Histolyticum for Dupuytren Disease: A Systematic Review

Effectiveness Collagenase Injection in the Treatment of Patients with Dupuytren Systematic Review

Therapie des Morbus Dupuytren mit Injektion von Kollagenase in Deutschland – Ergebnisse und Komplikationen an 110 Gelenken

Contact Info

Product

Resources

About